From Nobel Prize to clinical practice: An update on messenger RNA-based therapies for lipid disorders

No Thumbnail Available
File version
Author(s)
Hamilton-Craig, IR
Griffith University Author(s)
Hamilton-Craig, Ian
Primary Supervisor
Other Supervisors
Editor(s)
Date
2024
Size
File type(s)
Location
License
Abstract

The biological mechanism of gene silencing by messenger RNA (mRNA) inhibition has been harnessed to develop therapies to target specific proteins, such as those involved in lipid metabolism. The first of these, inclisiran, is available in Australia for reducing levels of LDL-cholesterol and is PBS listed for people with familial and nonfamilial hypercholesterolaemia.

Journal Title

Medicine Today

Conference Title
Book Title
Edition
Volume

25

Issue

7

Thesis Type
Degree Program
School
Publisher link
https://medicinetoday.com.au/mt/2024/july/regular-series/nobel-prize-clinical-practice-update-messenger-rnabased-therapies-lipid-disorders
DOI
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Persistent link to this record
https://hdl.handle.net/10072/432062
Citation

Hamilton-Craig, IR, From Nobel Prize to clinical practice An update on messenger RNA-based therapies for lipid disorders, Medicine Today, 2024, 25 (7), pp. 32-37

Collections
Journal articles